We know dealing with a condition such as Alzheimer’s disease can sometimes feel like an uphill battle, both for the patients and the caregivers. You feel like you’re not doing enough or as if the disease is taking up all your time and attention. To help you on your journey, we’ve gathered …
Alzheimer’s research is gaining momentum, with 27 Phase 3 and eight Phase 2 clinical trials either in progress or expected over the next five years. The good news surfaced in a revised pipeline analysis of Alzheimer’s therapies that researchers presented at the Alzheimer’s Association International Conference in London. The event, which started…
Axsome Therapeutics has announced that the first patient was enrolled in the ADVANCE-1 Phase 2/3 trial evaluating the effectiveness and safety of its investigative therapy AXS-05 for the treatment of agitation in Alzheimer’s disease patients. Agitation is related to anxiety and is reported by nearly 50 percent of Alzheimer’s patients. It’s…
AgeneBio has received a $750,000 grant from the Alzheimer’s Drug Discovery Foundation (ADDF) to support the development of a novel GABAA discovery program targeting hippocampal overactivity in the brain, which is thought to contribute to neurodegeneration and cognitive decline in Alzheimer’s disease (AD) patients. AgeneBio’s pipeline of therapies is…
William Glass, who has seen the devastating toll that Alzheimer’s disease inflicts on families as a caregiver for his mother, is setting out on a 640-mile walk from Atlanta to Washington, D.C., to raise awareness of the disease and advocate for Congress to increase funding for research. The Chicago native…
Araclon Biotech is launching a Phase 2 clinical trial evaluating its active immunotherapy, or vaccine, ABvac40 for Alzheimer’s disease, after receiving approval from the Spanish Agency of Medicinal Products and Medical Devices. The multi-center trial will include 22 European clinical facilities (18 centers in Spain, two in France, one in Sweden…
Anavex Life Sciences  has presented new information at a New York conference on Anavex 2-73, which prevented further decline in Alzheimer’s patients’ mental capacity in a clinical trial last year. Dr. Christopher U. Missling, Anavex’s president and chief executive officer, made the presentation at the Jefferies 2017 Global…
The $100 million IDEAS (Imaging Dementia — Evidence for Amyloid Scanning) Study is working closely with researchers and government officials to add three additional studies to the main project, where more than 18,000 people with cognitive deterioration but whose diagnosis is unclear are receiving a brain amyloid PET…
A new study found personalized music and memory therapy helped decrease antipsychotic and anti-anxiety medication use, as well as improve dementia symptoms, in people living with Alzheimer’s disease (AD) and related dementias (ADRD). Results from the study were published online in the American Journal of Geriatric Psychiatry, under the…
The National Institutes of Health (NIH) has awarded Pain Therapeutics a $1.7 million research grant to study PTI-125 as a potential treatment for Alzheimer’s disease. PTI-125 is an oral, small molecule drug developed by the Austin, Texas-based company in collaboration with other partners. It has been shown to significantly improve…
Get regular updates to your inbox.